CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 681 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01178086
NCT01178086N/ACompleted
CompareCT.gov

Rituximab in the Treatment of Chronic Lymphocytic Leukemia, "CLL NIS"

Hoffmann-La Roche·observational·Posted Aug 9, 2010·Updated Oct 5, 2018

In Brief

An observational study evaluating Rituximab for Lymphocytic Leukemia, Chronic. Completed, enrolled 681 participants across 1 site.

Detailed Summary

This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLymphocytic Leukemia, Chronic
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2010
Enrollment StartFeb 22, 2010
Primary CompletionJun 30, 2015
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 15.9 years ago

Interventions

Rituximabdrug

Rituximab IV